Literature DB >> 8117350

Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity.

S G Lim1, A M Sawyerr, M Hudson, J Sercombe, R E Pounder.   

Abstract

The study investigated the oral absorption of two antifungal agents, fluconazole and itraconazole, under conditions of low intragastric acidity. Twelve healthy male volunteers received each of 4 dosing regimens: 200 mg itraconazole alone, 200 mg itraconazole and famotidine, 100 mg fluconazole alone, and 100 mg fluconazole and famotidine. Two oral doses of 40 mg famotidine were used to induce hypochlorhydria. Serum drug concentrations were measured (by high pressure liquid chromatography) for 48 h after a single dose of each anti-fungal agent. When dosed with famotidine, there was a significant 52.9% decrease of the peak intraconazole concentration (P < 0.011), and a significant 51.1% decrease of the 48-h integrated serum intraconazole concentration (P = 0.005). Famotidine-induced hypochlorhydria did not affect the absorption of fluconazole.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8117350     DOI: 10.1111/j.1365-2036.1993.tb00103.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  19 in total

1.  Limited-sampling strategy models for itraconazole and hydroxy-itraconazole based on data from a bioequivalence study.

Authors:  G Suarez-Kurtz; F A Bozza; F L Vicente; C G Ponte; C J Struchiner
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

3.  Inhibition of antifungal therapy by gastric acid suppressants.

Authors:  Harry W Daniell
Journal:  Intensive Care Med       Date:  2015-02-21       Impact factor: 17.440

Review 4.  Antibiotic dosing in critically ill patients with acute kidney injury.

Authors:  Rachel F Eyler; Bruce A Mueller
Journal:  Nat Rev Nephrol       Date:  2011-02-22       Impact factor: 28.314

5.  Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis.

Authors:  J Reynes; C Bazin; F Ajana; A Datry; J P Le Moing; E Chwetzoff; J C Levron
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 6.  Pharmacology of itraconazole.

Authors:  K De Beule; J Van Gestel
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.

Authors:  Gopal Krishna; Allen Moton; Lei Ma; Matthew M Medlock; James McLeod
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 8.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

9.  Soluble itraconazole in tablet form using disordered drug delivery approach: critical scale-up considerations and bio-equivalence studies.

Authors:  Shankar Swaminathan; Mayur Sangwai; Sharad Wawdhane; Pradeep Vavia
Journal:  AAPS PharmSciTech       Date:  2013-01-19       Impact factor: 3.246

Review 10.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.